Company Overview - XuanYan BioTechnology Co., Ltd. was established on April 29, 2021, and is headquartered in the China (Shanghai) Pilot Free Trade Zone [3] - The company focuses on clinical research services and the transformation of research results, operating in the fields of biotechnology and pharmaceutical technology [5] Core Products and Technologies - The company offers AI-based lymph node metastasis detection kits specifically for thyroid cancer, along with supporting AI-assisted diagnostic software [6] - The product aims to address clinical decision-making scenarios such as lymph node metastasis detection and cancer recurrence monitoring [9] Financing History - Recently, XuanYan Bio completed a new round of financing led by DeTong Capital, with the funds primarily aimed at advancing the clinical validation and application of its AI-driven precision diagnosis products [2] - The financing history includes a Pre-A round on January 28, 2026, raising several tens of millions, and an angel round on October 23, 2023, also raising several tens of millions [8] Patent Situation - The company has several patents related to predicting lymph node metastasis risks and surgical decision support, utilizing a self-developed "integrated omics + AI" big data analysis platform [9][10] - Ongoing research pipelines include detection for esophageal cancer lymph node metastasis, urinary tract cancer recurrence monitoring, and breast cancer lymph node metastasis and recurrence detection [9]